Darlene Dobkowski, MA

In this on-demand webinar series, CURE partnered with Susan G. Komen Foundation and Roswell Park Comprehensive Cancer Center to discuss supporting others with breast cancer.

Regenerative Medicine Advanced Therapy designation was granted to an investigational CAR-T cell therapy for some patients with renal cell carcinoma.

An expert discussed how patients with breast cancer, particularly those with a BRCA mutation, should consider future fertility and breastfeeding when making treatment decisions.

Treatment with Scemblix was shown to improve response rates in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.

Jylamvo is an oral liquid formulation of methotrexate originally approved in 2022 for adults with acute lymphoblastic leukemia, among other diseases.

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

An expert discussed how liquid and tissue biopsies can help monitor treatment and detect potential resistance in patients with non-small cell lung cancer.

Through regular follow-ups and symptom assessments, breast cancer survivors have the access to physical and emotional support they may need.

An expert explained the advantages and disadvantages of radiation as a treatment for patients with renal cell carcinoma, a type of kidney cancer.

The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder cancer, does not affect other indications of the therapy.

An expert discussed the importance of patients learning about their specific type of breast cancer to understand potential treatment options.

An expert discussed how the understanding of resistance mechanisms can help care teams develop a global treatment strategy for EGFR-mutated non-small cell lung cancer.

With approaches like high intensity focused ultrasound, patients with prostate cancer may experience lower rates of urinary incontinence and erectile dysfunction, an expert said.

In this on-demand webinar series, CURE partnered with SHARE Cancer Support to learn more about other challenges of breast cancer outside of treatment.

In this on-demand webinar series, CURE partnered with SHARE Cancer Support to learn more about emotional well-being as a patient and survivor of breast cancer.

Asking physicians how they perform less-invasive surgeries for breast cancer can help reassure patients that their lymphedema risk is kept in mind.

In this on-demand webinar series, CURE partnered with SHARE Cancer Support to learn more about experiences with cancer from two breast cancer survivors.

An oral gel to manage oral mucositis — or chemo mouth — may help alleviate the effects of the side effect related to chemotherapy and radiotherapy.

An expert discussed options young patients with breast cancer may have to preserve their fertility before starting cancer treatment.

An expert discussed the importance of biomarkers in guiding treatment decisions for patients with metastatic breast cancer.

A Keytruda-based regimen given both before and after surgery for patients with head and neck squamous cell carcinoma may improve event-free survival.

An expert explained how radiation may be a treatment option for patients with renal cell carcinoma to manage symptoms and control the disease.

The drug combined with chemotherapy demonstrated a 60% increase in progression-free survival, suggesting signs of an FDA approval.

Removing more lymph nodes during surgery may also increase the risk for death after surgery in muscle-invasive bladder cancer.

CLD-101 is a novel stem cell-based treatment that delivers oncolytic viruses to tumors, which may benefit patients with newly diagnosed high-grade glioma.

This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other solid tumor types.

For patients with metastatic colorectal cancer, adding a higher dose proves just as effective as the standard dose of vitamin D3, despite one exception.

The biologics license application seeks potential approval of a Darzalex Faspro-based regimen for newly diagnosed multiple myeloma ineligible for transplant.

An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.

The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic HER2-low or -ultralow breast cancer.